Table 2.

Mitochondrial targeted drugs in consideration for cardiovascular diseases (CVD)

Number	Mito Target	Drug Name	Relevance in CVD	References
1	Mitochondrial fission/fusion drugs	DRP1, Opa1 targets- mdivi-1, Dynasore, P110,	I/R injury, inhibits proliferation	[13,21]
		Mfn targets- S3 (15-oxospiramilactone)		[34]
2	Sirtuins	SRT2104 and SRT2379, SRT1720, SRT2379	Metabolic diseases, atherosclerosis	[35]
3	Respiratory chain inhibitors	Complex I-Amobarbital, Metformin, Rotenone	I/R, TIA, ischemic stroke	[36]
		Complex III- Antimycin A, Myxothiazole	I/R	[37]
		Complex IV-H2S (Complex IV)	MI, arrhythmia, hypertrophy, fibrosis, IR and Heart failure	[38]
4	F1F0-ATPase inhibitors/Proton channel blockers	Aurovertin, Resveratrol	Ischemia, I/R, cardiomyopathy	[39]
		PK1119, Bz-423, Diindolyl methane, Apoptolidin, Oligomycin	Cardiac fibrosis	[40]
5	PT pore inhibitors	4′-chlorodiazepam (ro5-4684)	Arrhythmia, I/R	[41]
		Cyclosporin (CsA), Sanglifehrin A, Debio 025, NIM811	Reperfusion injury, Post-MI injury	[42]
		TRO40303	I/R	[43]
6	NO analogs	MitoSNO1, Nitrolipids, Nitrite, SNO-MPG	I/R, CHF	[44]
7	Potassium channel openers	Atpenin A5, BMS-191095, Cromakalim, Diazoxide, Malonate, Minoxidil, NS11021, NS1619, Pinacidil	I/R, MI, infarct size-limiting effect of ischemic preconditioning, myocardial reperfusion hyperoxygenation, improved cardiac contractile activity	[45]
8	RISK pathway modulators	Lithium, SB216763	Ischemic stroke, I/R	[46]
		Statins	prevent acute life-threatening coronary events	[47]
9	Aldehyde dehydrogenase 2	alpha-lipoic acid	Hypertension, I/R,	[48]
		Alda1	ventricular functioning/HF	[49]
10	Metabolic modulators	A-769662, Acadesine (AICAR), DCA, Etomoxir, GIK, Idebenone, L-arginine, Oxfenicine, perhexiline, ranolazine, trimetazidine	Hypertension, Ischemia, heart remodeling,	[50]